The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - AstraZeneca; Clovis Oncology (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); MSD; MSD (Inst); Synthon (Inst)
 
Junsik Park
No Relationships to Disclose
 
Jae Kwan Lee
No Relationships to Disclose
 
Dae Hoon Jeong
No Relationships to Disclose
 
Se Ik Kim
No Relationships to Disclose
 
Min Chul Choi
No Relationships to Disclose
 
Byoung-Gie Kim
No Relationships to Disclose
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boryung; GI Innovation; Takeda
Research Funding - AstraZeneca; CKD pharm; Clovis Oncology; OncoQuest
 
Jeong-Yeol Park
No Relationships to Disclose